An article published in The New York Times covers the exciting story about the groundbreaking oral treatment for gonorrhea, Zoliflodacin, acing its phase 3 clinical trials.

The nonprofit, GARDP, developed the antibiotic in collaboration with an American pharmaceutical company called Innoviva Specialty Therapeutics. The nonprofit sponsored the Phase 3 trial of the drug. In exchange, it holds the license to sell the antibiotic in about 160 countries while Innoviva retains marketing rights for high-income countries.

With shared investments and a strong focus on ensuring broader accessibility, especially in low- and middle-income countries, the development of this drug marks a shift in how antibiotic development is approached.

“I’ll go out on a limb and say that’s probably the only way in which we develop antibiotics going forward, because the old model is simply not going to work,” said OHT’s Dr. Ramanan Laxminarayan, chair of the Board of GARDP.

Find the article here.